Market News

Abbott Labs (ABT)

Abbott today dedicated its new Abbott Nutrition facility at the Research Park on the University of Illinois campus.
Abbott will use the facility to research and develop nutritional products for infants through adults. The company, which operates more than 100 facilities worldwide and sells products in more than 130 countries, will initially collaborate with faculty and students in the College of Agricultural, Consumer and Environmental Sciences. The company is beginning with 11 student interns and full time management.

Oct 23 · 11:37:00 AM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

IDEXX Laboratories (IDXX)

IDEXX Laboratories, Inc. today reported that revenues for the third quarter of 2009 were $259.1 million compared to $251.1 million for the third quarter of 2008. Organic revenue growth, as defined below, was 5%. Earnings per diluted share for the quarter ended September 30, 2009 grew 24% to $0.52 from $0.42 for the same period in the prior year.

Oct 23 · 11:30:00 AM · Source: Company News
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Gilead Sciences (GILD)

Gilead Sciences reported Q3 earnings of $0.72 per share on net income of $673 million compared to $0.52 per share on net income of $496 million in the year ago period.
Product sales increased 23 percent to a record $1.65 billion for the third quarter of 2009, compared to $1.34 billion in the third quarter of 2008. This increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth in sales of Truvada® (emtricitabine/tenofovir disoproxil fumarate), as well as the addition of Ranexa®Â (ranolazine) to our commercial portfolio.

Oct 22 · 3:06:00 PM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb reported Q3 earnings of $0.52 per share on net income of $5.49 billion versus $0.45 per share on net income of $5.24 billion in the year ago period.
“The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution,” said James M. Cornelius, chairman and chief executive officer.

Oct 22 · 11:37:00 AM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Amgen (AMGN)

Amgen reported Q3 earnings of $1.49 on net income of $1.5 billion versus $1.23 on net income of $1.3 billion in the year ago period. Total revenue decreased 2% during the quarter to $3.8 billion.
"Our third quarter results reflect the continued stability of our core businesses in the face of increased competition," said Kevin Sharer, chairman & chief executive officer. "We are pleased by the results of clinical studies for denosumab and Vectibix that we recently presented at a scientific meeting, and look forward to making these innovative medicines available to patients in their respective indications."

Oct 22 · 10:47:00 AM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Merck (MRK)

Merck & Co.'s (MRK) third-quarter profit more than tripled on a gain from the sale of the drug maker's stake in an animal-health joint venture, while a continued rebound in a blockbuster asthma drug helped overall sales inch higher.
For the three months ended Sept. 30, Merck reported net income of $3.4 billion, or $1.61 a share, up from $1.09 billion, or 51 cents a share, a year earlier. The latest quarter included a gain of $1.7 billion from Merck's sale of its 50% interest in the Merial animal-health joint venture to Sanofi-Aventis SA (SNY), which already owned the other half.

Oct 22 · 9:24:00 AM · Source: Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Gilead Sciences (GILD)

Gilead reported Q3 earnings of $0.72 per share on net income of $673 million versus $0.52 per share on net income of $495.9 million in the year ago period.
The results beat the average analyst forecast of 67 cents a share. Quarterly revenue rose 31% to $1.8 billion.

Oct 21 · 3:11:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb announced plans to close its Evansville, Indiana quality control facility effective December 31 and to implement a reduction in force at its Mount Vernon, Indiana facility.
In a Worker Adjustment and Retraining Notification Act (WARN) filing Tuesday with the Indiana Department of Workforce Development, the company said it anticipates 113 full-time employees will be separated from employment. Of those, 79 are employed at Evansville and 34 at Mount Vernon, according to the filing.

Oct 21 · 12:22:00 PM · Source: m.courrierpress
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next